Objective: This study aimed to identify the oncogenes at 20q involved in colorectal adenoma to carcinoma progression by measuring the effect of 20q gain on mRNA expression of genes in this amplicon.
Introduction
The majority of cancers are epithelial in origin and arise through a stepwise progression from normal cells, through dysplasia, into malignant cells that invade surrounding tissues and have metastatic potential. The colorectal adenoma to carcinoma progression is a classic example of this process [1] [2] .
Genomic instability is a crucial step in this progression and occurs in two ways in colorectal cancer (CRC) [3] . DNA mismatch repair defi ciency leading to microsatellite instability (MIN), explains about 15% of cases [4] [5] [6] . In the other 85%, genomic instability occurs at the chromosomal level (CIN) giving rise to aneuploidy. While for a long time chromosomal aberrations have been regarded as random noise, it is now well established that these DNA copy number changes occur in specifi c patterns and are associated with different clinical behaviour [7] [8] [9] . Nevertheless, neither the cause of chromosomal instability in human cancer progression nor its biological consequences have been fully appreciated.
Chromosomal aberrations frequently reported in CRC are 7pq, 8q, 13q, and 20q gains and 4pq, 5q, 8p, 15q, 17p, and 18q losses [10] [11] [12] [13] . Of these, especially 8q, 13q and 20q gains and 8p, 15q, 17p and 18q losses are associated with colorectal adenoma to carcinoma progression.
Gain of 20q is observed in more than 65% of CRCs [14] . Gains of 20q are also common in other tumour types and have been associated with poor outcome in gastric and CRC [15] [16] [17] [18] [19] [20] . The 20q13 amplicon has been studied in detail in breast and gastric cancers with restricted contig arrayCGH, pinpointing several genes as targets of amplifi cation [21] [22] . Analysis of DNA copy number changes at gene level by multiplex ligation-dependent probe amplifi cation (MLPA) showed that in CRC, besides 20q13, also 20q11 is frequently amplifi ed [23] .
This study aims to investigate dosage effects of putative 20q oncogenes in colorectal adenoma to carcinoma progression.
Material and Methods

Tumour samples
Forty-one formalin-fi xed and paraffi n-embedded progressed adenomas (with a focus of carcinoma present, also referred as malignant polyps) collected from the tissue archive of the department of pathology at the VU University medical center (VUmc), Amsterdam, the Netherlands and 73 prospectively collected snap-frozen colorectal tumour samples (37 non-progressed adenomas and 106 | Chapter 6 36 carcinomas) were investigated. All samples were used in compliance with the institution's ethical regulations.
The 41 progressed adenomas corresponded to 19 females and 18 males (three patients presented more than one lesion). Mean age was 67 (range . From these, adenoma and carcinoma components were analysed separately adding to a total of 82 archival samples (41x2).
The 73 frozen specimens corresponded to 31 females and 34 males (six patients had multiple tumours). Mean age was 69 (range . All histological sections were evaluated by a pathologist (G.A.M.).
Array CGH was performed on both sets of samples while expression microarrays were performed on the frozen samples only.
DNA and RNA isolation
DNA from paraffi n was obtained as described previously [24] . RNA and DNA from snap-frozen tissues were isolated using TRIzol (Invitrogen, Breda, The Netherlands) following the supplier's instructions with some modifi cations, described on http://www.english.vumc.nl/afdelingen/ microarrays. Isolated RNA was subjected to purifi cation using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). RNA and DNA concentrations and purities were measured on a Nanodrop ND-1000 spectrophotometer (Isogen, IJsselstein, The Netherlands) and integrity was evaluated on a 1% agarose ethidium bromide-stained gel.
Array CGH
A BAC/PAC (bacterial artifi cial chromosome/phage artifi cial chromosome) array platform was used as described elsewhere [25] . Arrays were scanned (Agilent DNA Microarray scanner G2505B-Agilent technologies, Palo Alto, USA) and Imagene 5.6 software (Biodiscovery, Marina del Rey, California) was used for automatic feature extraction with default settings. Local background was subtracted from the signal median intensities of both test and reference DNA. The median of the triplicate spots was calculated for each BAC clone and log2 ratios (tumour/normal) were normalized by subtraction of the mode value of BAC clones on chromosomes 1-22 (UCSC July2003 freeze of the Human Golden Path -NCBI Build 34). Clones with standard deviation of the intensity of the three spots >0.2 and with >20% missing values were excluded.
Expression microarrays
The Human Release 2.0 oligonucleotide library, containing 60mer oligonucleotides representing 28830 unique genes, designed by Compugen (San Jose, California, USA) was obtained from SigmaPutative oncogenes at chromosome 20q in colorectal carcinogenesis | 107
Genosys (Zwijndrecht, The Netherlands). Printing of slides was done as described elsewhere [26] .
Tumour RNA (30 μg) was hybridised against Universal Human reference (Stratagene, Amsterdam, The Netherlands). cDNA labelling and hybridisation procedures are described elsewhere [26] .
Scanning of arrays and feature extraction were performed as described above. Overall quality of experiments was judged on microarray plots of intensities of raw data. Normalization was done either with TIGR Midas (http://www.tm4.org/midas.html), using "Lowess" correction [27] or with "Median" normalization and implemented in the maNorm function (Marray R bioconductor package), with identical results. Interarray normalization was also performed. Low intensity values were replaced by the intensity value of 50. Genes with >20% missing values were excluded.
Array CGH and expression microarray data sets are available at Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/ [28] , accession number GSE8067.
Microarray data analysis
Below, the steps of data analysis are discussed for array CGH data, expression data and integrative analysis. To account for multiple testing, either a false discovery rate (FDR) correction was applied to the P values, or a very stringent P value cut-off was used.
Array CGH data
To segment DNA copy number alterations, a smoothing algorithm "aCGH-Smooth" was applied [29] . Smoothed log2 ratios of -0.15 and 0.15 were used as thresholds to defi ne gains and losses (99% CIs) obtained for 15 normal-to-normal hybridisations. Only gains and losses covering at least three consecutive BAC clones were included. Amplifi cations were called when log2 ratios exceeded 1.0. DNA copy number data were stored in ArrayCGHbase [30] (http://arraydb.vumc. nl/arrayCGHbase). Median absolute deviation (MAD) was determined for each case as a quality control. Cases with MAD ≥0.2 were excluded. Array CGH profi les were visualized in ArrayCGHbase.
Supervised analysis, comparing two groups, was done using CGHMultiArray [31] . For analysis of paired samples (adenoma and carcinoma components within progressed adenomas) an adapted version of CGHMultiArray was used, based on the Wilcoxon sign-rank test corrected for ties.
Reported p values are adjusted for multiple testing (FDR), unless stated otherwise.
For defi ning the most frequent smallest regions of overlap (SRO) for gains on 20q, throughout all cases, STAC (Signifi cance Testing for Aberrant Copy-number) was used [32] .
Microarray expression data
As all hybridisations were performed against a common reference, all comparisons were relative between colorectal adenomas and carcinomas.
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Supervised analysis for comparing carcinomas and adenomas was done using the Wilcoxon signed rank test, and a modifi ed version of this test-total Thas score (http://www.cvstat.ugent.be/index. php?page=techrep/techrep.htm) that is powerful when the distributions of the expression levels of both groups do not differ over the whole range of expression levels. This occurs when not all cases in the carcinomas and adenomas groups have differentially expressed genes, but differences rather appear in subpopulations. Genes were considered as differentially expressed when a Wilcoxon test p value <1e-5 and a Thas P value <0.05, corresponding to a FDR <0.05.
To disclose genes which expression is infl uenced by 20q gain, tumours with and without 20q gain were compared. Gene expression was regressed on copy number count using a linear model.
To evaluate the discriminatory power of candidate genes for classifying adenomas vs carcinomas, a stepwise linear discriminant analysis with leave one out cross-validation was performed on mRNA expression data (SPSS 15.0 for Windows, SPSS, Chicago, Illinois, USA).
Integration of copy number and expression data
ACE-it (Array CGH Expression integration tool) was applied to test whether gene dosage affects RNA expression [33] . Only genes on chromosome 20 are presented. We used a cut-off value of 0.15 for gains and losses, a default group value of 9 and a FDR ≤0.10.
Quantitative reverse transcription-PCR (qRT-PCR)
RNA (1 μg) was treated with DNase I and reverse transcribed to cDNA using oligo(dT)20 Primer with Superscript II reverse transcriptase (Invitrogen).
qRT-PCR was performed in duplicate on 15 adenomas and 15 carcinomas for six candidate genes. 
Immunohistochemistry on tissue microarrays (TMAs)
A TMA was constructed with 57 tumours (32 adenomas and 25 carcinomas) of which array CGH and/or expression microarray data were available. Of each tumour three cores from different Putative oncogenes at chromosome 20q in colorectal carcinogenesis | 109 locations within the tumour were included in the array. A 4 μm section of the array was used for immunohistochemistry. After deparaffi nation in xylene, and rehydration through graded alcohol to water, endogenous peroxidase was blocked with hydrogen peroxide (0.3% H2O2/methanol) for 25 min. Antigen retrieval was done by autoclaving in citrate buffer (10 mM; pH 6.0). Primary Aurora A monoclonal antibody NCL-L-AK2 from Novocastra Laboratories (Newcastle, UK) was incubated overnight at 4°C in a dilution of 1:50. The secondary antibody, K4006, mouse, from Envision kit (DAKO, Heverlee, Belgium) was incubated for 30 min at room temperature. Counterstaining was done with Mayer's hematoxylin. Incubation without primary antibody was used as negative control.
The colorectal cancer cell line Caco-2, which has a 20q gain and is known to express Aurora A, was used as positive control. Caco-2 cells were fi xed and paraffi n embedded, sections of which were taken along in the same run of immunohistochemistry as the TMA was processed. Caco-2 produced strong nuclear, mostly along with cytoplasmic, staining in >75% of tumour cells and this pattern was taken as reference for intense staining. Next, the spectrum of staining in the respective cores on the TMA was surveyed. in terms of intensity and positive nuclei. Only staining in tumour cells (i.e. either adenoma or carcinoma cells) was considered. Cores of the TMA typically contained 4-17 crypts with in every crypt >100 cells which all were evaluated. Basically, three staining patterns were seen; no staining at all, strong staining comparable to that observed in Caco-2 cells, and an intermediate pattern that showed positive staining, but clearly less intense than in Caco-2 cells.
The intensity of staining was taken as most important parameter. In pattern 2, typically 50% to 75% of nuclei showed intense staining, while in pattern 1 typically 25% to 75% of nuclei showed weak staining. For score 0, no more than a scattered weakly positive cell was tolerated. Based on evaluation of up to three cores by two independent observers, a score ranging from 0 to 2 was assigned per tumour, with score 0 corresponding to no signal, score 2 corresponding to the strong signal that was observed in the positive control Caco-2 and score 1 for an intermediate intensity staining. In case of disagreement between observers, a third observer was consulted and the majority score was noted.
Cochran-Armitage test analysis was performed to compare protein expression with lesion type (adenoma, carcinoma). Jonckheere-Terpstra test was performed to compare protein expression with log2 ratios (microarray expression data). Both tests make explicit use of the ordinality of the protein levels of expression. Differences were considered signifi cant when P<0.05.
Results
Delimiting gained regions on 20q
We analysed by array CGH 41 progressed adenomas, which were previously studied by classical CGH. We analysed the adenoma and carcinoma components of these samples separately. Gain of 20q occurred in >60% of the cases ( Figure 1A, 1B) . The pattern of copy number changes did not differ between adenoma and carcinoma components (as determined by CGHMultiArray), although sometimes showed lower amplitudes in the adenoma component ( Figure 1A, 1B) . Next, we analysed DNA copy number status of 37 non-progressed adenomas and 36 carcinomas.
From these 73 tumours, 67 (34 adenomas and 33 carcinomas) showed high quality genomic profi les with MAD values <0.2, giving an 8% drop-out. In these 67 tumours, chromosome 20 gain occurred in <15% of the adenomas but in >60% of the carcinomas (P<0.00001, as determined by CGHMultiArray), mostly affecting either all of chromosome 20 or the q-arm only, similar to the progressed adenomas ( Figure 1C, 1D ).
To determine the most relevant regions within 20q harbouring putative oncogenes with a role in colorectal adenoma to carcinoma progression, STAC [32] was applied to the combined set of 
Identifi cation of differentially expressed genes
We performed microarray expression analysis on the 37 non-progressed adenomas and 36 carcinomas of which snap-frozen material was available. High quality expression array data were obtained from 68 cases (37 adenomas and 31 carcinomas, 7% drop-out).
Supervised data analysis for identifying putative oncogenes on 20q, was done in two different ways;
we compared carcinomas to adenomas, and we compared tumours with 20q gain to tumours without 20q gain. The fi rst approach revealed genome-wide 122 up-regulated genes and 219 downregulated genes (a total of 341 differentially expressed genes), in carcinomas when compared to adenomas (Wilcoxon test p value <1e-5 (FDR <0.05) and Thas P-value <0.05). Of these 122 upregulated genes, 14 map at chromosome 20q (Table 1) . For the second approach, only tumours (adenomas and carcinomas) that had both array CGH data and expression data available (n=64)
were included. As a preselection, we used genes differentially expressed (both up and down) between carcinomas and adenomas, as we focus on genes at 20q that are involved in progression, using a less stringent cut-off (Thas P value <0.05). Thereby, we identifi ed 127 genes genome-wide out of 931 differentially expressed genes (regression analysis; FDR ≤0.1), whose expression levels are infl uenced by the occurrence of 20q gain. Of these 127 genes, 21 are mapped at 20q (Table 2) .
Nine genes common to these two approaches emerged, namely TPX2, C20orf24, AURKA, RNPC1, TH1L, ADRM1, C20orf20, TCFL5 and C20orf11.
Integration of array CGH and expression data
BAC array CGH data were related to oligonucleotide expression array data, independently of adenoma or carcinoma status, using a dedicated integration tool called ACEit [33] . We obtained a list of 151 genes located at chromosome 20 for which gene dosage affected expression levels (FDR ≤0.1), 120 of which are on the q-arm (Supplementary table 2 Stepwise linear discriminant analysis with leave one out cross validation showed that mRNA expression levels of two out of the seven candidate genes -that is, RNPC1 and TCFL5-allowed to correctly classify 88.2% of the cases (60/68) as adenomas or carcinomas ( Figure 5 and table 3 ). From 68 tumours in total, 60 were correctly classifi ed (88.2%), using expression levels of RNPC1 and TCLF5 only. 
Confi rmation of differential expression by qRT-PCR
qRT-PCR was performed on a sub-sample (n=30) of frozen tumours (15 adenomas and 15 carcinomas) to confi rm the expression levels of six of the seven genes identifi ed.
Carcinomas showed higher expression of all 6 genes compared to adenomas and tumours with 20q gain (4 adenomas and 8 carcinomas) showed higher expression compared to tumours without 20q gain (11 adenomas and 7 carcinomas). Table 4 shows the fold changes observed between either, carcinomas and adenomas or, tumours with 20q gain vs tumours without 20q gain, by microarrays and by qRT-PCR.
In situ confi rmation of AURKA expression by immunohistochemistry on TMAs yielded higher expression of AURKA in carcinomas compared to adenomas (P=0.01) ( Table 5 ) as well as a signifi cant positive correlation with the mRNA expression levels (P=0.01) ( Figure 6 ). Validation of other genes was hampered by the absence of adequate antibodies. 
Discussion
One of the most frequent chromosomal aberrations observed in CRC is gain of the long arm of chromosome 20. Nonetheless, which of the many genes mapping at 20q show altered expression due to DNA copy number alterations and play a role in the progression of colorectal adenoma to carcinoma, is not yet fully understood. In order to try to identify these putative oncogenes, we analysed a series of colorectal tumours, both adenomas and carcinomas at the DNA and RNA level.
In this study we confi rmed that chromosome 20 was the most frequently altered in the progressed adenomas and carcinomas (in >60% of cases). In non-progressed adenomas, gains of 20q were detected in <20%, supporting a role of 20q gain in colorectal adenoma to carcinoma progression consistent with earlier observations [7] . Narrowing down the gained region by array CGH across and 94 genes, respectively, including AURKA, PTK6 and EEF1A2. Altogether, based on copy number alterations alone the number of genes is still too high (209 genes, in total) to really pinpoint the genes that play a role in the progression of colorectal adenoma to carcinoma.
Comparison of the expression of carcinomas relatively to adenomas using strict statistical parameters showed that 14 genes mapping at 20q were overexpressed in carcinomas as compared to adenomas. Most of these genes were not described in previous expression microarray studies comparing adenomas to carcinomas [36] [37] . These studies used either Affymetrix arrays representing 6600 genes or cDNA microarrays representing 23000 genes as oppose to the 28830 represented on our oligonucleotides arrays. In addition, the number of samples analysed in the present study is considerably higher, with 4 to 10 times more adenomas and 2 to 3 times more carcinomas. In combination with our multi-angle, integrative data analysis the power of the present study thus is higher. Two genes that have been described as being over-expressed in colon tumours, compared to normal mucosa, are ADRM1 and TOMM34 [38] . Moreover, cDNA expression analysis in a series of clinical samples of CRC patients showed frequent up-regulation of TOMM34 in carcinomas and inhibition of this gene by siRNA in HCT116 colon cancer cell line drastically reduced the cell growth [39] . Together, these fi ndings corroborate our results since ADRM1 and TOMM34 are on the list of genes that showed to be up-regulated in carcinomas (compared to adenomas) ( Table 1 ). This lends support to the approach of the present study, and suggests that also the other candidates identifi ed might be relevant.
Looking at the same expression data from a different angle -that is, comparing the expression of tumours with and without 20q gain-we aimed to fi nd genes with a dosage effect on expression. Nine genes overlapped between the 14 adenoma vs carcinoma genes and the 21 genes associated with either or not 20q gain, namely TPX2, C20orf24, AURKA, RNPC1, TH1L, ADRM1, C20orf20, TCFL5
and C20orf11.
TPX2 and AURKA, differentially expressed between carcinomas and adenomas and associated with 20q gain, are known to be related to aneuploidy and interact with each other [42] . Moreover, in a microarray based chromosomal instability (CIN) gene signature, TPX2 ranked fi rst [43] . This fi nding supports the hypothesis that chromosome 20q gain has an important role in colorectal adenoma to carcinoma progression cancer, and that the onset of manifest CIN is instrumental.
Our third approach, integration of DNA copy number changes and gene expression demonstrated that throughout the genome 507 genes showed a statistically signifi cant association between DNA copy number and mRNA expression status, both for amplifi ed/up-regulated and deleted/ down-regulated genes, 120 of these being located on chromosome 20q. Some well known genes like, ZNF217 and CSE1L, previously reported to be amplifi ed in colon cancer [44] [45] [46] Little is known about the function of most of these genes. Some are transcription factors, like TCFL5 [47] , or otherwise involved in transcriptional regulation, like C20orf20 [48] . TH1L product is 122 | Chapter 6 involved in regulation of A-Raf kinase [49] . ADRM1 encodes for a putative cell adhesion molecule that recently was shown to be component of the 26S proteosome [50] . RNPC1 product is predicted to bind to RNA, based on sequence motifs and C20orf24 interacts with Rab-5, although its precise function is still unknown. AURKA has been well characterized and is involved in cell cycle regulation. It has been shown to be amplifi ed in CRC [51] and its overexpression induces centrosome amplifi cation, aneuploidy and transformation in vitro [52] . Moreover, inhibiting AURKA by RNA interference lead to growth suppression of human pancreatic cancer cells [53] . Knocking down TCFL5 resulted in suppression of the number of multicellular HT29 tumour spheroids, supporting its role in cancer development [54] .
In summary, we demonstrated the involvement of three SROs in the 20q amplicon in CRC and showed strong DNA copy number-mRNA expression associations for seven genes in these areas.
In addition we demonstrated signifi cant differences between colorectal adenomas and carcinomas at the DNA, mRNA and, for a one of the genes, at the protein level, supporting an important role as oncogenes in colorectal adenoma to carcinoma progression. Furthermore we showed that expression levels of two out of the seven genes allowed to discriminate adenomas from carcinomas with high accuracy. These genes therefore may both serve as highly specifi c biomarkers for CRC and as possible targets for pharmaceutical intervention in the development of CRC. 
